Chrysotherapy: A synoptic review

Inflammation Research

Volumn 52, Issue 12, 2003, Pages 487-501

  Eisler, R ^a  

^a PATUXENT WILDLIFE RESEARCH CENTER   (United States)

Author keywords

Gold drug therapy; Rheumatoid arthritis

Indexed keywords

4 AMINO 2 AUROTHIOSALICYLATE SODIUM; ALLOCHRYSINE; ANTIRHEUMATIC AGENT; AURANOFIN; AUROTHIOGLUCOSE; AUROTHIOMALATE; AZATHIOPRINE; BROMINE DERIVATIVE; COLLOIDAL GOLD; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GOLD BROMIDE; GOLD CHLOROQUINONE; GOLD COMPLEX; GOLD CYANIDE; GOLD DERIVATIVE; GOLD SALT; METHOTREXATE; MYCHRISIS; NONSTEROID ANTIINFLAMMATORY AGENT; ORGANOGOLD; QUINONE DERIVATIVE; SODIUM AUROTHIOSULFATE; UNCLASSIFIED DRUG;

ACUTE KIDNEY TUBULE NECROSIS; ACUTE PANCREATITIS; ANGINA PECTORIS; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; APLASTIC ANEMIA; AUTOIMMUNE DISEASE; BRAIN DISEASE; CARCINOMA; CLINICAL FEATURE; CLINICAL TRIAL; COLITIS; CONFUSION; CONTACT SENSITIVITY; CYTOTOXICITY; DERMATITIS; DISORIENTATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; ENTEROCOLITIS; EOSINOPHILIA; ERYTHEMA NODOSUM; EXFOLIATIVE DERMATITIS; FLUSHING; GASTROINTESTINAL SYMPTOM; GLOMERULONEPHRITIS; GOLD THERAPY; HEART INFARCTION; HEPATITIS; HISTORY OF MEDICINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGAMMAGLOBULINEMIA; HYPOTENSION; IMMUNE DEFICIENCY; IMMUNOMODULATION; INTELLECTUAL IMPAIRMENT; KIDNEY INJURY; LEPROSY; LICHEN PLANUS; LICHENOID; LICHENOID ERUPTION; LIVER DYSFUNCTION; LIVER NECROSIS; LIVER TOXICITY; LUNG CANCER; LUNG DISEASE; LYMPHADENOPATHY; MALARIA; MENTAL DISEASE; MOUTH INFLAMMATION; MYALGIA; NAUSEA; NEPHROTIC SYNDROME; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROPATHY; NONHUMAN; OSTEOLYSIS; PAPULAR SKIN DISEASE; PARAKERATOSIS; PAROTID GLAND DISEASE; PIGMENT EPITHELIUM; PITYRIASIS ROSEA; PROTEIN URINE LEVEL; PROTEINURIA; PRURITUS; PSORIATIC ARTHRITIS; PURPURA; RASH; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN ALLERGY; SKIN DISEASE; SKIN MANIFESTATION; SKIN PIGMENTATION; SKIN TOXICITY; STOMATITIS; STROKE; TISSUE INJURY; TONGUE CANCER; TREATMENT OUTCOME; VOMITING;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; GOLD; HUMANS;

EID: 0346725856     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00011-003-1208-2     Document Type: Review

References (106)

1. Sadler PJ. The biological chemistry of gold: a metallo-drug and heavy-atom label with variable valency. Structure Bonding 1976; 29: 171-215.
2. Shaw CF III. Gold complexes with anti-arthritic, anti-tumour and anti-HIV activity. In: Farrell NC, editor. Uses of inorganic chemistry in medicine: Cambridge, UK: Roy Soc Chem 1999; 26-57.
3. Merchant B. Gold, the noble metal and the paradoxes of its toxicology. Biologicals 1998; 26: 49-59.
4. Asperger S, Cetina-Cizmek B. Metal complexes in tumour therapy. Acta Pharmaceut 1999; 49: 225-36.
5. Vohora D, Vohora SB. Elemental basis of epilepsy. Trace Elem Electro 1999; 16: 109-23.
6. Singh MP, Mishra M, Khan AB, Ramdas SL, Panjiyar S. Gold treatment for kala-azar. Brit Med J 1989; 299: 1318.
7. Suzuki S, Okubo M, Kaise S, Ohara M, Kasukawa R. Gold sodium thiomalate selectivity inhibits interleukin-5-mediated eosinophil survival. J Allergy Clin Immunol 1995; 96: 251-6.
8. Jones G, Brooks PM. Injectable gold compounds: an overview. Brit J Rheum 1996; 35: 1154-8.
9. Hostynek JJ. Gold: an allergen of growing significance. Food Chem Toxicol 1997; 35: 839-44.
10. 6. J Med Chem 1997; 40: 1937-9.
11. Tomioka H, King TE Jr. Gold-induced pulmonary disease: clinical features, outcome, and differentiation from rheumatoid arthritis. Amer J Respir Crit Care Med 1997; 155: 1011-20.
12. Wang Q, Janzen N, Ramachandran C, Jirik F. Mechanism of inhibition of protein-tyrosine phosphatases by disodium aurothiomalate. Biochem Pharmacol 1997; 54: 703-11.
13. Pandya AG, Dyke C. Treatment of pemphigus with gold. Arch Dermatol 1998; 134: 1104-7.
14. Ueda S. Nephrotoxicity of gold salts, D-penicillamine, and allopurinol. In: De Broe ME, Porter GA, Bennett WM, Verpooten GA, editors. Clinical nephrotoxins: renal injury from drugs and chemicals. Boston: Kluwer, 1998; 223-38.
15. Lacaille D, Stein HB, Raboud J, Klinkhoff AV. Longterm therapy of psoriatic arthritis: intramuscular gold or methotrexate? J Rheum 2000; 27: 1922-7.
16. Kamei H, Koide T, Kojima T, Hashimoto Y, Hasegawa M. Effect of gold on tumor-associated antigens. Cancer Biother Radiopharmaceut 1999; 14: 403-6.
17. Cagnoli M, Alama A, Barbieri F, Novelli F, Bruzzo C, Sparatore F. Synthesis and biological activity of gold and tin compounds in ovarian cancer cells. Anti-Cancer Drugs 1998; 9: 603-10.
18. Messori L, Abbate F, Marcon G, Orioli P, Fontani M, Mini E, et al. Gold(III) complexes as potential antitumor agents: solution chemistry and cytotoxic properties of some selected gold(III) compounds. J Med Chem 2000; 43: 3541-8.
19. Shapiro DL, Masci JR. Treatment of HIV associated psoriatic arthritis with oral gold. J Rheum 1996; 23: 1818-20.
20. Shaw CF III. The biochemistry of gold. In: Schmidbaur H, editor. Gold: progress in chemistry, biochemistry and technology. New York: John Wiley, 1999; 260-308.
21. Savvaidis Y, Karamushka VI, Lee H, Trevors JT. Microorganism-gold interactions. Biometals 1998; 11: 69-78.
22. 3] (HL = pyrazole and imidazole). J Inorg Biochem 2000; 78: 363-70.
23. Elsome AM, Hamilton-Miller JMT, Brumfitt W, Noble WC. Antimicrobial activities in vitro and in vivo of transition element complexes containing gold (I) and osmium (VI). J Antimicrobiol Chemotherapy 1996; 39: 911-18.
24. Paimela L, Leirisalo-Repo M, Kosunen TU. (1995) Effect of long term intramuscular gold therapy on the seroprevalence of Helicobacter pylori in patients with early rheumatoid arthritis. Ann Rheum Dis 1995; 54: 437.
25. Oba T, Ishikawa T, Yamaguchi M. Different effects of two gold compounds on muscle contraction, membrane potential and ryanodine receptor. Europ J Pharmacol 1999; 374: 477-87.
26. Chuke JC, Baker RS, Porter JD. Bell's palsy-associated blepharospasm relieved by aiding eyelid closure. Ann Neurol 1996; 39: 263-8.
27. Julian GG, Hoffman JF, Shelton C. Surgical rehabilitation of facial nerve paralysis. Otolaryngol Clinics North Amer 1997; 30: 701-26.
28. Abell KM, Baker RS, Cowan DE, Porter JD. Efficacy of gold weight implants in facial nerve palsy: quantitative alterations in blinking. Vision Res 1998; 38: 3019-23.
29. Choo PH, Carter SR, Seiff SR. Upper eyelid gold weight implantation in the Asian patient with facial paralysis. Plastic Reconstruct Surg 2000; 3: 855-9.
30. Jobe R. Lid loading with gold for upper lid paralysis. Plastic Reconstruct Surg 2000; 106: 735-6.
31. Misra A, Grover R, Withey S, Grobbelaar AO, Harrison DH. Reducing postoperative morbidity after the insertion of gold weights to treat lagophthalmos. Ann Plastic Surg 2000; 45: 623-8.
32. Gjuric M, Schagerl S. Gold prostheses for ossiculoplasty. Amer J Otol 1998; 19: 273-6.
33. Tange RA, de Bruijn AJG, Grolman W. Experience with a new pure gold piston in stapedotomy for cases of otosclerosis. Auris Nasus Larynx 1998; 25: 249-53.
34. Gromer S, Arscott LD, Williams CH Jr, Schirmer RH, Becker K. Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J Biol Chem 1998; 273: 20096-101.
35. Roberts JR, Shaw CF III. Inhibition of erythrocyte selenium-glutathione peroxidase by auranofin analogues and metabolites. Biochem Pharmacol 1998; 55: 1291-9.
36. Snowden N, Dietch DM, Teh LS, Hilton RC, Haeney MR. Antibody deficiency associated with gold treatment: natural history and management in 22 patients. Ann Rheum Dis 1996; 55: 616-21.
37. Zeidler HK, Kvien TK, Hannonen P, Wollheim FA, Forre O, Geidel H, et al. Progression of joint damage in early active severe rheumatoid arthritis during 18 months of treatment: comparison of low-dose cyclosporin and parenteral gold. Brit J Rheum 1998; 37: 874-82.
38. Yanni G, Nabil M, Farahat MR, Poston RN, Panayi GS. Intramuscular gold decreases cytokine expression and macrophage numbers in the rheumatoid synovial membrane. Ann Rheum Dis 1994; 53: 315-22.
39. ten Wolde S, Dijkmans BAC, van Rood JJ, Claas FHJ, de Vries RRP, Hazes JMW, et al. Human leucocyte antigen phenotypes and gold-induced remissions in patients with rheumatoid arthritis. Brit J Rheum 1995; 34: 343-6.
40. Maetzel A, Bombardier C, Strand V, Tugwell P, Wells G. How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: a survey. J Rheum 1998; 25: 2331-8.
41. Galindo-Rodriguez G, Avina-Zubieta JA, Fitzgerald A, Leclerq SA, Russell AS, Suarez-Almazor ME. Variations and trends in the prescription of initial second line therapy for patients with rheumatoid arthritis. J Rheum 1997; 24: 633-8.
42. Hashimoto K, Whitehurst CE, Matsubara T, Hirohata K, Lipsky PE. Immunomodulatory effects of therapeutic gold compounds. Gold sodium thiomalate inhibits the activity of T cell protein kinase C. J Clin Invest 1992; 89: 1839-48.
43. Canumalla AJ, Al-Zamil N, Phillips M, Isab AA, Shaw CF III. Redox and ligand exchange reactions of potential gold (I) and gold (III)-cyanide metabolites under biomimetic conditions. J Inorg Biochem 2001; 85: 67-76.
44. Jain R, Lipsky PE. Treatment of rheumatoid arthritis. Adv Rheum 1997; 81: 57-84.
45. Hill C, Pile K, Henderson D, Kirkham B. Neurological side effects in two patients receiving gold injections for rheumatoid arthritis. Brit J Rheum 1995; 34: 989-90.
46. Sander O, Herborn G, Bock E, Rau R. Prospective six year follow up of patients withdrawn from a randomised study comparing parenteral gold salt and methotrexate. Ann Rheum Dis 1999; 58: 281-7.
47. Choy EHS, Gambling L, Best SL, Jenkins RE, Kondeatis E, Vaughan R, et al. Nickel contamination of gold salts: link with gold-induced skin rash. Brit J Rheum 1997; 36: 1054-8.
48. Hamilton J, McInnes IB, Thomason EA, Porter D, Hunter JA, Madhok R, et al. Comparative study of intramuscular gold and methotrexate in a rheumatoid arthritis population from a socially deprived area. Ann Rheum Dis 2001; 60: 566-72.
49. Nilsson JR. Effects of a gold salt and its intracellular distribution in Tetrahymena. Acta Protozool 1993; 32: 141-50.
50. van Gestel A, Koopman R, Wijnands M, van de Putte L, van Riel P. Mucocutaneous reactions to gold: a prospective study of 74 patients with rheumatoid arthritis. J Rheum 1994; 21: 1814-19.
51. Goebel C, Kubicka-Muranyi M, Tonn T, Gonzalez J, Gleichmann E. Phagocytes render chemicals immunogenic: oxidation of gold (I) to the T cell-sensitizing gold (III) metabolite generated by mononuclear phagocytes. Arch Toxicol 1995; 69: 450-9.
52. Pickl WF, Fischer GF, Fae I, Kolarz G, Scherak O. HLA-DR1-positive patients suffering from rheumatoid arthritis are at high risk for developing mucocutaneous side effects upon gold therapy. Human Immunol 1993; 38: 127-31.
53. Kiely PDW, Herlbert MR, Miles J, Oliveira DBG. Immunosuppressant effect of gold on IgG subclasses and IgE; evidence for sparing of the Th2 responses. Clin Exper Immunol 2000; 120: 369-74.
54. Rau R, Herborn G, Menninger H, Sangha O. Progression in early erosive rheumatoid arthritis: 12 month results from a randomized controlled trial comparing methotrexate and gold sodium thiomalate. Brit J Rheum 1998; 37: 1220-6.
55. Rasanen L, Kaipiainen-Seppanen O, Myllykangas-Luosujarvi R, Kasanen T, Pollari P, Saloranta P, et al. Hypersensitivity to gold in gold sodium thiomalate-induced dermatosis. Brit J Dermatol 1999; 141: 683-8.
56. Bendix G, Bjelle A. A 10 year follow up of parenteral gold therapy in patients with rheumatoid arthritis. Ann Rheum Dis 1996; 55: 169-76.
57. Tilelli JA, Heinrichs MM. Adverse reactions to parenteral gold salts. Lancet 1997; 349: 853.
58. Whitehouse MW, Graham GG. Is local biotransformation the key to understanding the pharmacological activity of salicylates and gold drugs? Inflamm Res 1996; 45: 579-92.
59. Graham GG, Kettle AJ. The activation of gold complexes by cyanide produced by polymorphonuclear leukocytes. III. The formation of aurocyanide by myeloperoxidase. Biochem Pharmacol 1998; 56: 307-12.
60. Zou J, Guo Z, Parkinson JA, Chen Y, Sadler PJ. Gold(III)-induced oxidation of glycine: relevance to the toxic side-effects of gold drugs. J Inorg Biochem 1999; 74: 352.
61. Abraham GE, Himmel PB. Management of rheumatoid arthritis: rationale for the use of colloidal metallic gold. J Nutrit Environ Med 1997; 7: 295-305.
62. Griem P, Gleichmann E. Das Antirheumatikum Gold: Erwunschte und unerwuschte Wirkungen von Au(I) und Au(II) auf das Immunsystem. Z Rheum 1996; 55: 348-58.
63. Hirohata S, Nakanishi K, Yanagida T, Kawai M, Kikuchi H, Isshi K. Synergistic inhibition of human B cell activation by gold sodium thiomalate and auranofin. Clin Immunol Immunopathol 1999; 91: 226-33.
64. Sanders M. A review of controlled clinical trials examining the effects of antimalarial compounds and gold compounds on radiographic progression in rheumatoid arthritis. J Rheum 2000; 27: 523-9.
65. Yadav R, Misra R, Naik S. In vitro effect of gold sodium thiomalate and methotrexate on tumor necrosis factor production in normal healthy individuals and patients with rheumatoid arthritis. Inter J Immunopharmac 1997; 9: 111-14.
66. Bratt J, Belcher J, Vercellotti GM, Palmblad J. Effects of anti-rheumatic gold salts on NF-kB mobilization and tumor necrosis factor-α(TNF-α)-induced neutrophil- dependent cytotoxicity for human endothelial cells. Clin Exper Immunol 2000; 120: 79-84.
67. Mangalam AK, Aggrawal A, Naik S. Mechanism of action of disease modifying anti-rheumatic agent, gold sodium thiomalate (GTM). Int Immunopharmacol 2001; 1: 1165-72.
68. Hall TJ, Jeker H, Nyugen H, Schaeublin M. Gold salts inhibit osteoclastic bone resorption in vitro. Inflamm Res 1996; 45: 230-3.
69. Newman PM, To SST, Robinson BG, Hyland VJ, Schreiber L. Effect of gold sodium thiomalate and its thiomalate component on the in vitro expression of endothelial cell adhesion molecules. J Clin Invest 1994; 94: 1864-71.
70. Sato H, Yamaguchi M, Shibasaki T, Ishii T, Bannai S. Induction of stress proteins in mouse peritoneal macrophages by the antirheumatic agents gold sodium thiomalate and auranofin. Biochem Pharmacol 1995; 49: 1453-7.
71. Heimburger M, Lerner R, Palmblad J. Effects of antirheumatic drugs on adhesiveness of endothelial cells and neutrophils. Biochem Pharmacol 1998; 56: 1661-9.
72. Handel ML. Transcription factors AP-1 and NF-κB: where steroids meet the gold standard of anti-rheumatic drugs. Inflamm Res 1997; 46: 282-6.
73. Brown DH, Smith WE. The chemistry of the gold drugs used in the treatment of rheumatoid arthritis. Chem Soc Rev (London) 1980; 9: 217-40.
74. Hirohata S. Inhibition of human B cell activation by gold compounds. Clin Immunol Immunopathol 1996; 81: 175-81.
75. + monocyte-lineage cells from bone marrow of rheumatoid arthritis patients. Clin Immunol Immunopathol 1997; 84: 290-5.
76. Rau R, Schleusser B, Herborn G, Karger T. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy. J Rheum 1998; 25: 1485-92.
77. Janssen M, Dijkmans BAC, Vandenbroucke JP, van Duijn W, Pena AS, Lamers CBHW. Decreased levels of antibodies against Helicobacter pylori in patients with rheumatoid arthritis receiving intramuscular gold. Ann Rheum Dis 1992; 51: 1036-8.
78. Lockie LM, Smith DM. Forty-seven years experience with gold therapy in 1,019 rheumatoid arthritis patients. Semin Arthritis Rheum 1985; 13: 238-46.
79. Munro R, Hampson R, McEntegart A, Thomson EA, Madhok R, Capell H. Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five year prospective study. Ann Rheum Dis 1998; 57: 88-93.
80. Graudal IK, Graudal N, Jurik AG. On the course of seropositive rheumatoid arthritis during and after long-term gold therapy. Scandin J Rheum 1994; 23: 223-30.
81. Menninger H, Herborn G, Sander O, Blechschmidt J, Rau R. A 36 month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis. Brit J Rheum 1998; 37: 1060-68.
82. Biasi D, Caramaschi P, Carletto A, Pacor ML, Bambara LM. Combination therapy with hydroxychloroquine, gold sodium thiomalate and methotrexate in early rheumatoid arthritis. An open 3-year study. Clin Rheum 2000; 19: 505-7.
83. Duro JC, Andreu M. Gold induced colitis. J Rheum 1995; 22: 572-3.
84. Zuazua JS, Fuente AMG, Rodriguez JCM, Garcia GB, Rodriguez AP. Obstructive sialadenitis caused by intraparotid deposits of gold salts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996; 81: 649-51.
85. Manoubi L, Jaafoura MH, Skhiri-Zhioura A, El Hil A, Berry JP, Galle P. Subcellular localization of gold in suprarenal testicle and thyroid glands after injection of allochrysine in rats. Cell Molec Biol 1994; 40: 483-7.
86. Doney K, Storb R, Buckner CD, Thomas ED. Treatment of gold-induced aplastic anaemia with immunosuppressive therapy. Brit J Haematol 1988; 68: 469-72.
87. Munro R, Morrison E, McDonald AG, Hunter JA, Madhok R, Capell HA. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis 1997; 56: 374-7.
88. Bendix G, Bjelle A, Holmberg E. Cancer morbidity in rheumatoid arthritis patients treated with Proresid or parenteral gold. Scandin J Rheum 1995; 24: 79-84.
89. Fleming CJ, Salisbury ELC, Kirwan P, Painter DM, Barnetson FS. Chrysiasis after low-dose gold and UV light exposure. J Amer Acad Dermatol 1996; 34: 349-51.
90. Miller ML, Harford RR, Yeager JK, Johnson F. A case of chrysiasis. Cutis 1997; 59: 256-8.
91. Smith RW, Cawley MID. Chrysiasis. Brit J Rheum 1997; 36: 3-5.
92. Smith RW, Leppard B, Barnett NL, Millard-Sadler GH, McCrae F, Cawley MID. Chrysiasis revisited: a clinical and pathological study. Brit J Dermatol 1995; 133: 671-8.
93. Raza SA, Phillipps JJ. Bilateral tympanic membrane perforation - a result of gold toxicity? Brit J Dermatol 1997; 136: 479-80.
94. Evans TI, Small RE, Redford TW, Han J, Moxley G. Tumor necrosis factor microsatellite markers TNFa5b5 and TNFa6b5 influence adverse reactions to parenteral gold in caucasians. J Rheum 1999; 26: 2302-9.
95. ter Borg EJ, Ramselaar CG, Wiltink EHH. Nail shedding (Beau's lines) after severe gold dermatitis. Arthritis Rheum 2000; 43: 1420.
96. Stillman AE, Dubey DP. Immune functions and gold-induced enterocolitis. Digest Dis Sci 1988; 33: 1046-7.
97. Dorta G, Schnegg JF, Saraga E, Schmeid PA. Treatment of gold-induced enteritis with octreotide. Lancet 1993; 342: 179.
98. Mohr W, Gorz E. Morphology of gold deposits in stromal cells of the colonic mucosa after chrysotherapy. Akt Rheum 2000; 25: 103-5 (in German, English abstract)
99. Evron E, Brautbar C, Becker S, Fenakel G, Abend Y, Stroeger Z, et al. Correlation between gold-induced enterocolitis and the presence of the HLA-DRB1*0404 allele. Arthritis Rheum 1995; 38: 755-9.
100. Schumann D, Kubicka-Muranyi M, Mirtschewa J, Gunther J, Kind P, Gleichmann E. Adverse immune reactions to gold. I. Chronic treatment with an Au(I) drug sensitizes mouse cells not to Au(I), but to Au(III) and induces autoantibody formation. J Immunol 1990; 145: 2132-9.
101. Ben-Ami H, Pollack S, Nagachandran P, Lashevsky I, Yarnitsky D, Edoute Y. Reversible pancreatitis, hepatitis, and peripheral polyneuropathy associated with parenteral gold therapy. J Rheum 1999; 26: 2049-50.
102. Koryem HK, Taha KM, Ibrahim IK, Younes LK. Liver toxicity profile in gold-treated Egyptian rheumatoid arthritis patients. Int J Clin Pharm Res 1998; 18: 31-7.
103. Klinkhoff AV, Teufel A. Reinstitution of gold after gold induced proteinuria. J Rheum 1997; 24: 1277-9.
104. Wooley PH, Griffin J, Panyi GS, Batchelor JR, Welsh KI, Gibson TJ. HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. New England J Med 1980; 303: 300-2.
105. Dubowitz MN, Hughes PJ, Lane RJM, Wade JPH. Gold-induced neuroencephlopathy responding to dimercaprol. Lancet 1991; 337: 850-1.
106. Ganley CJ, Paget SA, Reidenberg MM. Increased renal tubular cell excretion by patients receiving chronic therapy with gold and with nonsteroidal anti-inflammatory drugs. Clin Pharmacol Therapeu 1989; 46: 51-5.